Correspondence 0001193125-24-127548 from Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc.
Date: May 1, 2024 · CIK: 0001806952 · Accession: 0001193125-24-127548
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277495
Letter
LYELL IMMUNOPHARMA, INC.
201 Haskins Way
South San Francisco, California 94080
VIA EDGAR
May 1, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tamika Sheppard
Re: Lyell Immunopharma, Inc.
Registration Statement on Form S-3
File No. 333-277495
Acceleration Request
Requested Date:
May 3, 2024
Requested Time:
4:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Lyell Immunopharma, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277495) (the “Registration Statement”) to become effective on May 3, 2024, at 4:30 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth Guernsey or Anitha Anne of Cooley LLP, our outside counsel, at (415) 693-2091 or (415) 693-2250. Thank you for your assistance with this matter.
Sincerely,
LYELL IMMUNOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 VIA EDGAR May 1, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 File No. 333-277495 Acceleration Request Requested Date: May 3, 2024 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Lyell Immunopharma, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277495) (the “Registration Statement”) to become effective on May 3, 2024, at 4:30 p.m. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth Guernsey or Anitha Anne of Cooley LLP, our outside counsel, at (415) 693-2091 or (415) 693-2250. Thank you for your assistance with this matter. Sincerely, LYELL IMMUNOPHARMA, INC. By: /s/ Matthew Lang Matthew Lang Chief Business Officer, Chief Legal Officer and Corporate Secretary